ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity

Diabetes. 2016 Jan;65(1):85-95. doi: 10.2337/db15-0399. Epub 2015 Jul 29.

Abstract

Obesity is increasing in prevalence and is strongly associated with metabolic and cardiovascular disorders. The renin-angiotensin system (RAS) has emerged as a key pathogenic mechanism for these disorders; angiotensin (Ang)-converting enzyme 2 (ACE2) negatively regulates RAS by metabolizing Ang II into Ang 1-7. We studied the role of ACE2 in obesity-mediated cardiac dysfunction. ACE2 null (ACE2KO) and wild-type (WT) mice were fed a high-fat diet (HFD) or a control diet and studied at 6 months of age. Loss of ACE2 resulted in decreased weight gain but increased glucose intolerance, epicardial adipose tissue (EAT) inflammation, and polarization of macrophages into a proinflammatory phenotype in response to HFD. Similarly, human EAT in patients with obesity and heart failure displayed a proinflammatory macrophage phenotype. Exacerbated EAT inflammation in ACE2KO-HFD mice was associated with decreased myocardial adiponectin, decreased phosphorylation of AMPK, increased cardiac steatosis and lipotoxicity, and myocardial insulin resistance, which worsened heart function. Ang 1-7 (24 µg/kg/h) administered to ACE2KO-HFD mice resulted in ameliorated EAT inflammation and reduced cardiac steatosis and lipotoxicity, resulting in normalization of heart failure. In conclusion, ACE2 plays a novel role in heart disease associated with obesity wherein ACE2 negatively regulates obesity-induced EAT inflammation and cardiac insulin resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Adiponectin / metabolism
  • Adipose Tissue / immunology*
  • Angiotensin I / pharmacology
  • Angiotensin-Converting Enzyme 2
  • Animals
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Blotting, Western
  • Diet, High-Fat*
  • Enzyme-Linked Immunosorbent Assay
  • Glucose Intolerance / genetics
  • Glucose Intolerance / metabolism
  • Heart / physiopathology
  • Heart Failure / genetics*
  • Heart Failure / immunology
  • Heart Failure / physiopathology
  • Humans
  • Inflammation / genetics
  • Inflammation / immunology
  • Insulin Resistance / genetics
  • Macrophages / immunology*
  • Mice
  • Mice, Knockout
  • Myocardium / metabolism*
  • Obesity / genetics*
  • Obesity / immunology
  • Obesity / physiopathology
  • Oxidative Stress
  • Peptide Fragments / pharmacology
  • Peptidyl-Dipeptidase A / deficiency*
  • Peptidyl-Dipeptidase A / genetics
  • Pericardium / immunology*
  • Phosphorylation
  • Real-Time Polymerase Chain Reaction
  • Stroke Volume
  • Tumor Necrosis Factor-alpha / immunology
  • Vasodilator Agents / pharmacology
  • Weight Gain / genetics

Substances

  • Adiponectin
  • Blood Glucose
  • Peptide Fragments
  • Tumor Necrosis Factor-alpha
  • Vasodilator Agents
  • Angiotensin I
  • AMP-Activated Protein Kinases
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Ace2 protein, mouse
  • Angiotensin-Converting Enzyme 2
  • angiotensin I (1-7)